CorMedix (CRMD) Competitors

CorMedix (NASDAQ:CRMD) and Protagonist Therapeutics (NASDAQ:PTGX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Do insiders & institutionals hold more shares of CRMD or PTGX?

34.2% of CorMedix shares are held by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are held by institutional investors. 5.3% of CorMedix shares are held by insiders. Comparatively, 4.9% of Protagonist Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Which has more volatility & risk, CRMD or PTGX?

CorMedix has a beta of 1.71, suggesting that its share price is 71% more volatile than the S&P 500. Comparatively, Protagonist Therapeutics has a beta of 2.33, suggesting that its share price is 133% more volatile than the S&P 500.

Does the media refer more to CRMD or PTGX?

In the previous week, CorMedix had 3 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 18 mentions for CorMedix and 15 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.67 beat CorMedix's score of 0.56 indicating that Protagonist Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CorMedix	3 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Protagonist Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts rate CRMD or PTGX?

CorMedix currently has a consensus target price of $16.71, suggesting a potential upside of 37.14%. Protagonist Therapeutics has a consensus target price of $67.20, suggesting a potential upside of 19.83%. Given CorMedix's higher probable upside, equities analysts plainly believe CorMedix is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CorMedix	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.88
Protagonist Therapeutics	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00

Is CRMD or PTGX more profitable?

CorMedix has a net margin of 42.11% compared to Protagonist Therapeutics' net margin of 24.88%. CorMedix's return on equity of 42.73% beat Protagonist Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CorMedix	42.11%	42.73%	34.19%
Protagonist Therapeutics	24.88%	8.12%	7.41%

Which has better earnings and valuation, CRMD or PTGX?

Protagonist Therapeutics has higher revenue and earnings than CorMedix. CorMedix is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CorMedix	$121.48M	7.49	-$17.93M	$0.75	16.25
Protagonist Therapeutics	$434.43M	8.03	$275.19M	$0.70	80.12

Summary

Protagonist Therapeutics beats CorMedix on 9 of the 16 factors compared between the two stocks.